<DOC>
	<DOC>NCT01130909</DOC>
	<brief_summary>This study will provide data to support preclinical to clinical translation by aligning preclinical and clinical efficacy assay with dose dependent changes in EEG.</brief_summary>
	<brief_title>A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765</brief_title>
	<detailed_description>A Phase I, Randomized, Double-Blind, Four-way Cross-over Study in Healthy Subjects to Assess Quantitative Electroencephalography (qEEG) parameters after the administration of ketamine, two doses of AZD6765 and Placebo</detailed_description>
	<mesh_term>Ketamine</mesh_term>
	<criteria>BMI 1830 Nonsmoker for at least 4 weeks Any clinically relevant acute or chronic disease History of substance abuse Hypersensitivity to ketamine</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Effect of a single dose on gamma-band qEEG</keyword>
</DOC>